Journal of Neural Transmission

, 114:1147

L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

  • M. Kuoppamäki
  • G. Al-Barghouthy
  • M. J. Jackson
  • L. A. Smith
  • N. Quinn
  • P. Jenner
Article

Summary

Most patients with Parkinson’s disease (PD) develop dyskinesia and other motor complications after prolonged L-dopa use. We now report on the relationship between L-dopa dose and the duration and severity of dyskinesia in L-dopa-primed MPTP-treated primates with marked nigral degeneration mimicking late stage PD. With increasing doses of L-dopa, locomotor activity increased and motor disability declined. The duration of dyskinesia following L-dopa administration increased dose-dependently, and showed a linear correlation with total locomotor activity. In addition, the time-course of dyskinesia paralleled closely that of locomotor activity in a dose-dependent manner. In contrast, severity of dyskinesia showed a non-linear correlation with total locomotor activity, low doses of L-dopa eliciting severe dyskinesia for short periods of time. The threshold for dyskinesia induction and the antiparkinsonian effects of L-dopa appear very similar in primed MPTP primates mimicking late stage PD. Reducing individual doses of L-dopa to avoid severe dyskinesia can markedly compromise the antiparkinsonian response. Our results extend the relevance of the dyskinetic MPTP-treated primate in studying the genesis of involuntary movements occurring in L-dopa treated patients with PD.

Keywords: Marmoset, Parkinson’s disease, priming, dyskinesia, involuntary movements 

References

  1. Agid, Y, Bonnet, AM, Ruberg, M, Javoy-Agid, F 1985Pathophysiology of L-dopa-induced abnormal involuntary movementsPsychopharmacology Suppl2145159PubMedGoogle Scholar
  2. Bédard, PJ, Di Paolo, T, Falardeau, P, Boucher, R 1986Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone bindingBrain Res379294299CrossRefPubMedGoogle Scholar
  3. Bejjani, BP, Arnulf, I, Demeret, S, Damier, P, Bonnet, AM, Houeto, JL, Agid, Y 2000Levodopa-induced dyskinesias in Parkinson’s disease: is sensitization reversible?Ann Neurol47655658CrossRefPubMedGoogle Scholar
  4. Boyce, S, Rupniak, NMJ, Steventon, MJ, Iversen, SD 1990Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeysPsychopharmacology1022127CrossRefPubMedGoogle Scholar
  5. Chase, TN, Oh, JD 2000Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonismTrends Neurosci23S86S91CrossRefPubMedGoogle Scholar
  6. Clarke, CE, Sambrook, MA, Mitchell, IJ, Crossman, AR 1987Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)J Neurol Sci78273280CrossRefPubMedGoogle Scholar
  7. Di Monte, DA, McCormack, A, Petzinger, G, Janson, AM, Quik, M, Langston, WJ 2000Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate modelMov Disord15459466CrossRefPubMedGoogle Scholar
  8. Jenner, P, Rupniak, NM, Rose, S, Kelly, E, Kilpatrick, G, Lees, A, Marsden, CD 19841-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmosetNeurosci Lett508590CrossRefPubMedGoogle Scholar
  9. Kostic, VS, Marinkovic, J, Svetel, M, Stefanova, E, Przedborski, S 2002The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complicationsEur J Neurol9914CrossRefPubMedGoogle Scholar
  10. Metman, LV, van den Munckhof, P, Klaassen, AA, Blanchet, P, Mouradian, MM, Chase, TN 1997Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson’s diseaseNeurology49711713PubMedGoogle Scholar
  11. Mones, RJ, Elizan, TS, Siegel, GJ 1971Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonismJ Neurol Neurosurg Psychiatry34668673CrossRefPubMedGoogle Scholar
  12. Mouradian, MM, Heuser, IJE, Baronti, F, Fabbrini, G, Juncos, JL, Chase, TN 1989Pathogenesis of dyskinesias in Parkinson’s diseaseAnn Neurol25523526CrossRefPubMedGoogle Scholar
  13. Nutt, JG 2000Clinical pharmacology of levodopa-induced dyskinesiaAnn Neurol47S160S166PubMedGoogle Scholar
  14. Nutt, JG 2002

    Motor fluctuations and dyskinesias

    Factor, SAWeiner, WJ eds. Parkinson’s diseaseDemos Medical PublishingNew York445453
    Google Scholar
  15. Nutt, JG, Woodward, WR 1986Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patientsNeurology36739744PubMedGoogle Scholar
  16. Nutt, JG, Woodward, WR, Carter, JH, Gancher, ST 1992Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenonArch Neuro4911231130Google Scholar
  17. Olanow, CW, Schapira, AHV, Rascol, O 2000Continuous dopamine-receptor stimulation in early Parkinson’s diseaseTrends Neurosci23S117S126CrossRefPubMedGoogle Scholar
  18. Pearce, RKB, Jackson, M, Smith, L, Jenner, P, Marsden, CD 1995Chronic L-DOPA administration induces dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)Mov Disord10731740CrossRefPubMedGoogle Scholar
  19. Pearce, RKB, Banerji, T, Jenner, P, Marsden, CD 1998De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmosetMov Disord13234241CrossRefPubMedGoogle Scholar
  20. Picconi, B, Centonze, D, Håkansson, K, Bernardi, G, Greengard, P, Fisone, G, Cenci, MA, Calabresi, P 2003Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesiaNature Neurosci6501506PubMedGoogle Scholar
  21. Rascol, O 2000Medical treatment of levodopa-induced dyskinesiasAnn Neurol47S179S188PubMedGoogle Scholar
  22. Schneider, JS 1989Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damagePharmacol Biochem Behav34193196CrossRefPubMedGoogle Scholar
  23. Schrag, A, Quinn, N 2000Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based studyBrain12322972305CrossRefPubMedGoogle Scholar
  24. Smith, LA, Gordin, A, Jenner, P, Marsden, CD 1997Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosetMov Disord12935945CrossRefPubMedGoogle Scholar
  25. Smith, LA, Jackson, MJ, Hansard, MJ, Maratos, E, Jenner, P 2000Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration and brain exposureMov Disord18487495CrossRefGoogle Scholar
  26. Smith, LA, Jackson, MJ, Al-Barghouthy, G, Rose, S, Kuoppamäki, M, Olanow, W, Jenner, P 2005Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP treated drug-naïve primatesMov Disord20306314CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Kuoppamäki
    • 1
    • 2
  • G. Al-Barghouthy
    • 1
  • M. J. Jackson
    • 1
  • L. A. Smith
    • 1
  • N. Quinn
    • 3
  • P. Jenner
    • 1
  1. 1.Neurodegenerative Diseases Research CentreKing’s CollegeLondonU.K.
  2. 2.Department of NeurologyTurku University HospitalTurkuFinland
  3. 3.Sobell Department of Motor Neuroscience and Movement DisordersInstitute of NeurologyLondonU.K.

Personalised recommendations